Rigel Pharmaceuticals (RIGL) Net Equity Issued and Repurchased (2010 - 2018)

Rigel Pharmaceuticals' Net Equity Issued and Repurchased history runs 9 years deep, the most recent figure standing at $8.8 million for Q2 2018.

• In Q2 2018, Net Equity Issued and Repurchased rose 183.38% year-over-year to $8.8 million; the TTM figure through Dec 2018 stood at $14.5 million (down 73.44% YoY), while the FY2018 annual figure was $67.2 million, down 41.18% from the prior year.
• Net Equity Issued and Repurchased for Q2 2018 stood at $8.8 million, up from $5.7 million in the prior quarter.
• The five-year high for Net Equity Issued and Repurchased was $43.1 million in Q1 2017, with the low at $5000.0 in Q3 2014.
• The 5-year median for Net Equity Issued and Repurchased is $2.6 million (2017), against an average of $6.5 million.
• The sharpest annual moves came in 2016 and 2017: Net Equity Issued and Repurchased jumped 32252.94% in 2016, then plunged 91.44% in 2017.
• Rigel Pharmaceuticals' Net Equity Issued and Repurchased stood at $480000.0 in 2014, then jumped by 767.71% to $4.2 million in 2015, then plunged by 68.79% to $1.3 million in 2016, then soared by 338.46% to $5.7 million in 2017, then jumped by 53.72% to $8.8 million in 2018.
• Business Quant data shows RIGL's Net Equity Issued and Repurchased at $8.8 million in Q2 2018, $5.7 million in Q4 2017, and $2.6 million in Q3 2017.